Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

APP Pharmaceuticals Inc.

Division of Fresenius SE & Co. KGaA
www.apppharma.com

Latest From APP Pharmaceuticals Inc.

Deal Watch: Seattle Genetics' Controversial Collaboration With Immunomedics Topples

A licensing deal between the two cancer-focused biotechs falls apart amidst investor unrest at Immunomedics. Novartis opts to license Conatus' Phase II NASH candidate and picks up a CAR-T candidate from Celyad, while Shire adds to its dry eye franchise in deal with Parion.

Deals M & A

Hospira's Angiomax Generic At Risk As Contract Manufacturing Gets Legal Reprieve

Federal Circuit en banc court reverses panel decision, giving The Medicines Company chance to prove infringement and get Hospira's generic off the market.

Legal Issues Legal Issues

Angiomax Generic From Hospira Might Launch At-Risk Launch In 2015

District Court upholds validity of TMC’s process patents for its anticoagulant but finds Hospira does not infringe them.

BioPharmaceutical United States

Filings In The Second Half Could Be Transformative For The Medicines Co.

The Medicines Co.’s transition away from near-total reliance on Angiomax seems ever closer to reality, given its full pipeline and intensive business development activities. The new products stretch beyond the hospital catheterization lab, as the company builds franchises in hospital anti-infectives, pain management, and hemostatis.

BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Medical Devices
    • Infusion Therapy Equipment and Supplies
  • Pharmaceuticals
    • Generic Drugs
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Fresenius SE & Co. KGaA
  • Senior Management
  • John Ducker, Pres. & CEO
    Richard J Tajak, EVP, CFO
    Christopher Bryant, PhD, EVP, CSO
  • Contact Info
  • APP Pharmaceuticals Inc.
    Phone: (847) 413-2075
    1501 E. Woodfield Rd.
    Ste. 300 East
    Schaumburg, IL 60173
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register